

Report

Junction

Annual Report

2007-2008

CERTIFIED TRUE COPY

For Welcure Drugs & Pharmaceuticals
Ltd.

Company Secretary



WELCURE DRUGS & PHARMACEUTICALS LTD.

WELCURE DRUGS & PHARMACEUTICALS LTD.

Welcure is an ISO 9001:2000 and WHO-GMP Norms Certified Company. **Welcure** has to its credit the most modern and sophisticated manufacturing facilities of international standards which include ultra-modern plant, machinery and equipment, own R & D, in house testing laboratory and captive power generation. **Welcure** manufactures a large variety of pharmaceutical formulations. Some of our known products include:

MEDICINE

IBUCURE & RELAXON FORTE

ACEWEL, DICLO PLUS, DIMCIN PLUS

NIMAGYL, NIMAGYL TD, NIMAGYL-PC

COLDREST, COLDHIST-EX

CEZEN, CEZEN FORTE, L-CEZEN

KUFFWEL, X-DRYL, X-DRYL FORTE

RENACT, OMEJEL, OMEJEL DM

LOPCURE

ACEWEL-MR, WELGESIC-MR

WORMICIDE

CEFPOWEL, CUREXIME

AZIWEL, WELOXY, CIPCIN, NORWEL, GATIWEL, OXCIN

WELQUIN

NORTIN, CIPCIN-TNZ

SERVO

B-REST

WELOXY-P, CEPHA-KID, NORKID

WELGRA

LIVOMAX, DROXWEL, CEFUROXIL

IVAWEL

MICAL

SPINACH

PNZOD

AVERINE

WEL Fe Na, MAXYRED, HAEMFLOW-Z

THERAPEUTICAL INDICATIONS

- ◆ BODY PAIN, JOINT PAIN, INFLAMMATIONS
- ◆ BODY PAIN, FEVER, JOINT PAIN
- ◆ RHEUMATOID ARTHRITIS, HEADACHE, ENT INFLAMMATIONS
- ◆ NASAL CONGESTION, MUSCULAR PAIN, HEADACHE, BODYACHE, SNEEZING
- ◆ ALLERGY, SNEEZING, SINUSITIS, COUGH, COLD
- ◆ ALLERGIC / DRY / SMOKER'S COUGH, HEADACHE & FEVER, ANTI COUGH TABLETS
- ◆ ULCERS, HYPERACIDITY, REFLUX, GASTRITIS, STOMACH SPASM & PAIN
- ◆ LOOSE MOTIONS & DIARRHEA
- ◆ POTENT ANTI-INFLAMMATORY ANALGESIC & MUSCLE RELAXANT
- ◆ ROUNDWORMS, HOOKWORMS, THREADWORMS ETC.
- ◆ ANTIBIOTIC FOR URTI INCLUDING PHARYNGITIS & TONSILLITIS
- ◆ STRONG ANTIBIOTIC FOR UPPER & LOWER RESPIRATORY INFECTIONS, SKIN INFECTION
- ◆ ANTI MALARIAL
- ◆ POWERFUL ANTI BIOTICS & ANTI PROTOZOAL AGAINST INFECTIONS
- ◆ POWERFUL ANTI INFLAMMATION IN PRE & POST OPERATIVE CASES, SINUSITIS
- ◆ ANXIETY, DEPRESSION, PANIC DISORDER
- ◆ PAEDIATRIC RANGE OF ANTIBIOTICS
- ◆ TREATMENT OF ERECTILE DYSFUNCTION
- ◆ BROAD SPECTRUM ANTIBIOTIC FOR URINARY TRACT & SOFT TISSUE INFECTIONS
- ◆ SCABIES, PEDICULOSIS, FILARIASIS, INTESTINAL NEMATODE INFECTION
- ◆ HEALTHY PREGNENCY
- ◆ LOW BACK PAIN, CERVICAL SPONDYLITIS, STIFF NECK, SPRAIN & STRAIN
- ◆ HYPERACIDITY, DYSPEPSIA
- ◆ RENAL COLICS, POST OPERATIVE PAIN, BILARY COLICS
- ◆ TREATMENT FOR IRON DEFICIENCY

सर्वे भवन्तु सुखिनः
सभी स्वस्थ हों, सुखी हों, समृद्ध हों।



WELCURE DRUGS & PHARMACEUTICALS LTD.

ISO 9001:2000 AND WHO-GMP CERTIFIED COMPANY

Board of Directors

Shri D. C. Jain (Mg. Director)
Shri S. S. Dhanoa
Shri R. K. Pandey
Shri Shri Nath Prasad Ojha
Shri M. L. Bhateja
Shri Sudhir Chandra

Audit Committee

Shri R. K. Pandey, Chairman
Shri S. S. Dhanoa
Shri M. L. Bhateja
Shri Sudhir Chandra
Shri Shri Nath Prasad Ojha

Shareholders & Investors Grievance Committee

Shri R. K. Pandey, Chairman
Shri S. S. Dhanoa
Shri M. L. Bhateja
Shri Sudhir Chandra

Remuneration Committee

Shri R. K. Pandey, Chairman
Shri S. S. Dhanoa
Shri M. L. Bhateja
Shri Sudhir Chandra

Accounts Committee

Shri D.C.Jain, Chairman
Shri R.K.Pandey
Shri M. L. Bhateja

Company Secretary

Perna Suneja

Auditors

Gauba, Gauba & Associates

Internal Auditors

Gitika Dang

Cost Auditors

Aseem Jain, Cost Accountant

Bankers

State Bank of India

Factory & Regd. Office

Welcure Drugs & Pharmaceuticals Ltd.
A-1129, RIICO Industrial Area, Phase-III,
Bhiwadi-301019 (Rajasthan)

Corporate Office

301-305, Mohan Palace,
L.S.C., C Block,
Saraswati Vihar, Delhi-34

Share Transfer Agent

Intime Spectrum Registry Ltd.,
A-40, 2nd Floor, Naraina Industrial Area,
Phase-II, Near Batra Banquet Hall,
New Delhi-110028

WELCURE DRUGS & PHARMACEUTICALS LIMITED

DIRECTORS REPORT :

Directors hereby present the Sixteenth Annual Report together with Audited Statements of Account of the Company for the year ended 31st March 2008.

FINANCIAL RESULTS Sales & Profitability :

The Total sales of the company together with the sales of its wholly owned subsidiary company is Rs. 25.78 crores for the year 2007-08 as compared to Rs. 25.35 Crores for the year 2006-07. The combined net loss is Rs. 1.90 crores for the year 2007-08 as compared to net loss of Rs. 0.81 crores in the previous year. The consolidated Income & Profitability Statement of the Company is as under :

Figures in Rs. Lacs

Particulars	Welcure		Subsidiary Co.		Consolidated	
	2007-08	2006-07	2007-08	2006-07	2007-08	2006-07
Sales	2548	1879	30	666	2578	2535
Other Income	109	152	-	-	109	152
Total Income	2657	2031	30	666	2687	2687
Expenditure	2754	2065	26	625	2780	2680
Interest	53	24	-	17	53	41
Depreciation	42	42	1	1	43	43
Provision for taxation	0	0	1	4	1	4
Profit after tax	(192)	(90)	2	9	(190)	(81)

Apart from its own manufacture & sales, the Company manufactured products for mainly fortwo other companies on Loan Licence Basis and earned an Income of Rs. 108.70 lacs as against previous year earning of Rs. 152.00 lacs.

The main reasons for increase in the loss include: writing off of deferred revenue expenditure of Rs. 90.91 lacs (previous year 30.30 lacs), short fall in job earnings by Rs. 43.30 lacs and manufacturing of own products becoming un-remunerative. Also certain bad debts had to be written off.

Sale of manufactured goods had been Rs. 303.53 lacs (previous year Rs.391.50) and sale of purchased goods had been Rs.2244.42 lacs (previous year Rs. 1487.54 lacs)

Because of MRP based Excise in Rajasthan as against Excise

free Zones in various other states. Scope for manufacturing products for own sales has practically come to an end.It may therefore be worthwhile to sell the unit, if possible and shift its registered office to Delhi.

EXPORTS

During the year under review, the Company made indirect exports of Rs. 101.47 lacs. (Previous year Rs.165.06 lacs).

DIVIDEND

In view of loss in the current year and accumulated losses, the Directors do not recommend any dividend for the year under review.

ISO 9001 : 2000 CERTIFICATION

The company is continuing to hold certification of ISO 9001:2000 The Company maintains highest standards of Quality matching International requirements.

DIRECTORS' RESPONSIBILITY STATEMENT

Directors hereby state that:

1. In the preparation of Annual Accounts, the applicable accounting standards have been followed;
2. We have selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the company for that period;
3. We have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 1956 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
4. We have prepared the Annual Accounts on a going concern basis.

DIRECTORS

Shri R.K.Pandey and Shri Sudhir Chandra retire by rotation at the ensuing Annual General Meeting and are eligible for re-appointments. The Board recommends their re-appointments.

WELCURE DRUGS & PHARMACEUTICALS LIMITED

SUBSIDIARY COMPANIES

In terms of section 212 of the Companies Act, 1956, the Particulars of Subsidiary Company; and in terms of section 211(3)(C) of the Companies Act 1956, read with Accounting Standard 21, issued by the Institute of Chartered Accountants of India, a Consolidated Financial Statement of Welcure Drugs & Pharmaceutical Ltd. & its wholly owned subsidiary A. K. Laboratories Ltd. are being included in the Annual Accounts of the Company.

PARTICULARS OF EMPLOYEES

During the year ended 31st March 2008, there was no employee drawing remuneration in excess of the amount prescribed under section 217(2A) of the Companies Act. 1956.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS & OUTGO

Information pursuant to Companies (Disclosure of Particulars in Report of Board of Directors) Rules, 1988 is given as under:

(A) CONSERVATION OF ENERGY

Optimum energy conservation steps are being taken to reduce per unit cost but purchase prices of diesel and electricity are increasing. Power factor is being monitored continuously as energy conservation measure. Efforts are made to save energy due to power factor improvement, maintenance of proper voltage supply and proper load distribution. Power & fuel consumption details are as under:

	2007-08	2006-07
(i) Units (Lacs) of Electricity Purchased (RSEB)	4.54	4.99
(ii) Total Amount (Rs. Lacs)	23.08	24.42
(iii) Rate per Electricity Unit (Rs.)	5.08	4.89
(iv) Unit (Lacs) Own Generation (through D.G. Set)	0.12	0.16
(v) Diesel Oil (Ltrs in Lacs)	0.07	0.08
(vi) Cost per unit (Rs.)	17.32	14.80

(B) TECHNOLOGY ABSORPTION -Company is continuing to bring improvement in quality & processes.

(C) FOREIGN EXCHANGE EARNINGS & OUTGO – NIL

LISTING FEE OF SHARES

The Company's Shares are listed with The Stock Exchange Mumbai and up to date Listing Fee is paid.

MANAGEMENT DISCUSSION ANALYSIS & CORPORATE GOVERNANCE REPORT

In terms of the Listing Agreement, Management Discussion and Analysis Report and a report on Corporate Governance along with the Auditor's report are annexed and forms part of the Annual Report.

COST AUDIT

In terms of section 233 (1-B) of the Companies Act, 1956, M/s Aseem Jain & Associates, Cost Accountants have been duly appointed as Cost Auditors of the Company, for the financial year 2007-08.

AUDITORS

M/s Gauba, Gauba & Associates, Chartered Accountants, retire at the forthcoming Annual General Meeting and have given confirmation to the effect that their re-appointment, if made, would be in conformity with the limits specified under section 224 (1-B) of the Companies Act, 1956.

ACKNOWLEDGMENT

Directors place on record their thanks for the support extended to the Company by its Customers, Dealers, Suppliers, Bankers, Employees, Investors, Medical Professionals, and other Government and local authorities.

For & on behalf of the Board of
Directors

Place : Delhi
Date : 31.05.2008

D. C. Jain, Chairman

WELCURE DRUGS & PHARMACEUTICALS LIMITED

CORPORATE GOVERNANCE REPORT

1. WELCURE'S PHILOSOPHY

Welcure believes in adopting the Best Global management practices in the area of Corporate Governance and follow the principles of full transparency and accountability, thereby protecting the interests of all its stakeholders, and fulfilling the social obligation entrusted upon corporate sector.

The Board considers itself a Trustee of all Shareholders and acknowledges its responsibilities to the Shareholders for creating and safeguarding Shareholders' Wealth. During the year under review, the Board continued its pursuit of achieving these objectives through the adoption and monitoring of corporate strategies, prudent business plans, monitoring of major risks of the Company's business and ensuring that the Company pursues policies and procedures to satisfy its legal and ethical responsibilities.

2. BOARD OF DIRECTORS

The Board consists of the following:

(a) Promoter & Executive Director:

Shri D. C. Jain, B. Com., LL.B., M.I.L (Hons.), G.D.I.M., M.I.I.A., A.M.I.B.M. F.A.S.M., F.C.S. is Chairman cum Managing Director and founder of the Company and has over four decades experience in controlling various industries as top level Company Executive. He had been President of the Institute of Company Secretaries of India. He is a Director of two other companies.

(b) Independent Executive Director:

Shri S.N.P. Ojha, B.Sc., has approximately 15 years of experience in manufacture of pharmaceuticals including 5 years experience with the Company. He has adequate technical qualification & knowledge; and has also been approved as Competent Manufacturing Chemist by Drugs Control Department, Rajasthan. He is in-charge and Director responsible for day-to-day affairs of Bhiwadi Factory including Compliance of Drugs and other Laws relating to Factory.

(c) Independent Non-Executive Directors:

Shri R. K. Pandey, M.Com., D.B.A., LL.B., F.C.S. is a leading Financial Consultant with a high Financial and Accounting background. He had been Executive Director of the Delhi Stock Exchange Association Ltd for 16 years and Financial Advisor to a U.P Government Undertaking. He is the Chairman of the Company's Audit Committee, Remuneration Committee, Accounts Committee and Shareholders and Investors Grievance Committee. He is a Director of nine other companies, and member of three Board Committees of these companies.

Shri S.S. Dhanoa, I.A.S (Retd.), B.Sc., LL.B., GSPiA (Pittsburgh U.S.A) had been Election Commissioner of India, Health Secretary, Government of India and Chief Secretary, Punjab.

He is a Director and Board Committee member of one more Company. He is member of the Company's Audit Committee, Remuneration Committee and Shareholders & Investors Grievance Committee.

Shri. M.L. Bhateja, B.Sc., has approximately 30 years of experience in the field of marketing of Bulk Drug and Pharmaceutical Formulations including Tablets, Capsules, Injection, Syrups, Dry Syrups, Ear and Eye Drops & Ointments. He had worked for 24 years with Ranbaxy Laboratories Limited as Regional Sales Manager. In one more he is a director and member in Company's Audit Committee, Remuneration Committee, Accounts Committee and Shareholders & Investors Grievance Committee.

Shri. Sudhir Chandra, B.Sc., B. Tech (Hons.) and Dip. (Ing.), has over 40 years working experience in Management & Systems including 4 years experience in Pharmaceuticals. He is highly experienced & matured person. His association has been with some of the leading industries in India and abroad, providing a high rate of work satisfaction throughout his career. He is not a director in any other company. He is a member in Company's Audit Committee, Remuneration Committee and Shareholders & Investors Grievance Committee.

(c) **Meetings** : Four Board Meetings were held during the financial year on 30.05.2007, 28.07.2007, 30.10.2007 and 28.01.2008. Last Annual General Meeting was held on 28.07.2007. The Annual General Meeting and all the four Board meetings were attended by all the Directors except the meeting held on 30.5.2007 not attended by Shri S.S. Dhanoa and Meetings held on 28.7.2007 not attended by Shri S.N.P. Ojha and Shri S.S. Dhanoa.

3. AUDIT COMMITTEE

(i) Constitution of Audit Committee

R.K. Pandey (Chairman of the Committee)	Non Executive Director
S.S. Dhanoa	Non Executive Director
M.L. Bhateja	Non Executive Director
Sudhir Chandra	Non Executive Director
S.N.P. Ojha	Executive Director

(ii) Functions of the Committee

(a) Review of periodical results before submission to the Board; Review of Annual Financial Statements before submission to the Board; especially with regard to the Directors Responsibility Statement, the changes in accounting policies and practices, major accounting entries, significant adjustments arising out of audit, the going concern assumption, compliance with accounting standards, compliance with stock exchange & legal requirements concerning Listing, Legal and

WELCURE DRUGS & PHARMACEUTICALS LIMITED

Financial Statements, Disclosures of related party transaction, qualification in the Audit Report.

- (b) Oversight of Company's Financial reporting process & disclosures for correctness, sufficiency & credibility; and to look into the reasons for substantial defaults in payment to depositors, creditors and government dues.
- (c) Reviewing performance of statutory and internal Auditors; adequacy of internal control systems; review findings, investigations & follow ups of Internal & External Auditor's appointment, removal, functioning, staffing, reporting structure and frequency of Internal audit.
- (d) Discussion with Auditors regarding their observation on accounts; and adequacy and compliance of internal control system.
- (e) Recommendation on appointment and removal of external auditor(s); and fixation of audit fee, out of pocket expenses and payment of other services.
- (f) Other compliances of Companies Act and Stock Exchange.
- (g) Carry out of any other function as per the terms of reference.

(iii) Powers of the Committee

- (a) To investigate into any activity within its terms of reference.
- (b) To access the information contained in the Company records
- (c) To seek information from any employee
- (d) To obtain and to have access to outside legal and other professional advice
- (e) To secure attendance of outsiders with relevant expertise
- (f) To bind the Board with its audit report on financial management.

(iv) Meetings

During the financial year Four Meetings of Audit Committee were held on 30.05.2007, 28.07.2007, 30.10.2007 and 28.01.2008; and were attended by all the Audit Committee members except the meetings held on 30.5.2007 not attended by Shri S.S. Dhanoa and meeting held on 28.07.2007 not attended by Shri S.N.P. Ojha and Shri S.S. Dhanoa.

4. ACCOUNTS COMMITTEE

Pursuant to amended Clause 41 of the Listing Agreement and in terms of Circular SEBI Circular No. SEBI/CFD/DIL/LA/3/2007/10/07 dated 10.7.2007 an Accounts Committee has been constituted during the year.

(i) Constitution of Accounts Committee

D.C.Jain (Chairman of the Committee) Managing Director
R.K.Pandey Non Executive Director
M.L. Bhateja Non Executive Director

(ii) Functions of the Accounts Committee

- (a) Approving the Quarterly Financial Results, if Board Meeting not being held.
- (b) Perusal of Limited Review Report.

(iii) Meetings

During the year two meetings of the Accounts Committee were held on 28.11.2007 and 25.02.2008 and were attended by all the Account Committee members except the meetings held on 28.11.2007 not attended by Shri M.L.Bhateja.

5. REMUNERATION COMMITTEE

(i) Constitution of Remuneration Committee

R. K. Pandey (Chairman of the Committee) Non Executive Director
S. S. Dhanoa Non Executive Director
M.L. Bhateja Non Executive Director
Sudhir Chandra Non-Executive Director

(ii) Functions of the Committee & Remuneration Policy

The committee is entrusted with the function and responsibility of approving the remuneration to be paid to the managerial personnel of the Company including its Directors, Whole Time Directors, Managing Director(s) and Relatives of Directors; whose remuneration is fixed within the ceiling limits prescribed by Government under Schedule XIII of the Companies Act 1956. Remuneration paid to directors during the financial year 2007-2008 is given under Notes to the Accounts. Functions of Remuneration Committee are entrusted and combined with Audit Committee.

6. SHAREHOLDERS AND INVESTORS GRIEVANCE COMMITTEE

Constitution of the Committee

R. K. Pandey (Chairman of the Committee) Non Executive Director
S.S. Dhanoa Non Executive Director
M.L. Bhateja Non Executive Director
Sudhir Chandra Non Executive Director

Functions of Shareholders and Investor Grievance Committee are entrusted and combined with Audit Committee.

6 GENERAL BODY MEETINGS

Last Four Annual General Meetings were held in Bhiwadi on 28.7.2004, 29.07.2005, 28.07.2006 all at 9.00 A.M. and 28.07.2007 at 5.15 P.M.. All resolutions at these meetings were passed by show of hands. Special resolution regarding shifting of registered Office from State of Rajasthan to National Capital Territory of Delhi is proposed by Postal Ballot.

WELCURE DRUGS & PHARMACEUTICALS LIMITED

8. DISCLOSURES

There were no transactions of the company of material nature with related parties that may have potential conflict with the interest of the company at large. No penalties or strictures were imposed on the Company by Stock Exchanges or SEBI or any statutory authority on any matter related to capital markets during the last three years.

9. MEANS OF COMMUNICATION

Annual reports of the Company are sent to each shareholder of the Company. Half-yearly/ Quarterly results are normally published in Financial Express and Jansatta newspapers and copies thereof are sent to the Stock Exchanges as per Listing Agreement.

10. MANAGEMENT DISCUSSION & ANALYSIS

Management-Discussion & Analysis is being included in the Annual Report.

11. CODE OF CONDUCT

The Board has formulated a code of conduct for the Board members and Senior management Personnel of the Company. All Board members and Senior management personnel have affirmed their compliance with the code.

12. DISCLOSURE ON RISK MANAGEMENT

The Company had laid down procedure to minimize and to inform Board Members about the risk assessment and management, which is periodically reviewed by the Board.

13. CEO/CFO CERTIFICATION

A Certificate from the CEO/CFO on the financial statement of the Company was placed and considered by the Board.

AGM: Date, Time & Venue			28-07-2008; 9:00 AM; A-1129, RIICO Industrial Area,Phase III, Bhiwadi									
Financial Calendar			01-04-2007 to 31-03-2008									
Date of Book Closure			14-7-2008 to 28-7-2008 (both days inclusive)									
Dividend Payment Date			No Dividend proposed									
Stock Exchange Listing			Bombay Stock Exchange Ltd.									
Stock Code			Bombay – 524661									
Market Price Data & Performance Comparison												
Particulars	Apr 07	May 07	Jun 07	Jul 07	Aug 07	Sep 07	Oct 07	Nov 07	Dec 07	Jan 08	Feb 08	Mar 08
Low	4.00	4.00	3.73	3.90	4.06	4.96	4.07	3.93	6.11	5.99	5.00	4.07
High	4.70	4.97	5.01	5.50	6.89	6.17	5.34	5.82	12.15	14.74	7.60	6.10
Registrar & Transfer Agent			M/s Intime Spectrum Registry Ltd., A-40, 2 nd Floor, Naraina Industrial Area, Phase –II, Near Batra Banquet Hall, New Delhi-110028.									
Share Transfer System			All orderly received transfers are processed & returned within 30 days									
Dematerialization of Shares and Liquidity			Trading in a dematerialised form w.e.f. 27-02-2001 Connectivity with CDSL & NSDL 15-11-2000. ISIN No. INE331C01017 Shares traded at Bombay Stock Exchange, Mumbai, (BSE).									
Distribution of Share Holding as on AGM held on 28.07.2007			Directors and their Relatives 5444000 Shares 40.290% Body Corporate 2138956 Shares 15.83% Non resident Indians 242001 Shares 1.79% Others 5687143 Shares 42.09%									
Nominal Value of Shares (as on 28.07.2007)			No of shareholders		% to Total Shareholders		Total Amt. in Rs.		% to Total Amount			
Up to Rs. 2500			12012		67.857		15832730		11.717			
2501 5000			3738		21.116		14336580		10.610			
5001 10000			1254		7.084		10111660		7.483			
10001 20000			450		2.542		6889160		5.099			
20001 30000			94		0.531		2390940		1.769			
30001 40000			38		0.215		1358710		1.006			
40001 50000			32		0.181		1518260		1.124			
50001 100000			37		0.209		2559950		1.895			
100001 & above			47		0.266		80123010		59.297			
Total			17702		100.00		135121000		100.000			
Pending GDRs, ADRs etc.			Nil									
Plant Location			A-1129, RIICO Industrial Area, Phase-III, Bhiwadi, Rajasthan									
Correspondence Address			Regarding Shares: M/s Intime Spectrum Registry Ltd. , A-40, 2 nd Floor, Naraina Industrial Area, Phase –II, Near batra Banquet Hall, New Delhi-110 028 Of the Company: Welcure Drugs & Pharmaceuticals Ltd., A-1129, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan or 305, LSC, Mohan Place, Block-C, Saraswati Vihar, Delhi-110034.									